【SynerG】The company's outstanding balance of capital loans has reached the announcement standard of Article 22, Paragraph 1, Subparagraph 3 of the 'Regulations Governing Loaning of Funds and Endorsements/Guarantees by Public Companies'

1. Date of occurrence of the event: 2026/05/06 2. Recipient of capital loans: (1) Company name: Jih Ho Medical Instruments Co., Ltd. (2) Relationship with the company providing capital loans: 100% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 200,000 (5) Amount of new capital loan (NT$ thousand): 100,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 300,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Duo Mo Shi Co., Ltd. (2) Relationship with the company providing capital loans: 100% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 450,000 (5) Amount of new capital loan (NT$ thousand): 50,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 500,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Shin Hwa Bio-Tech Co., Ltd. (2) Relationship with the company providing capital loans: 100% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 600,000 (5) Amount of new capital loan (NT$ thousand): 100,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 700,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Jiu He Bio-Tech Co., Ltd. (2) Relationship with the company providing capital loans: 100% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 60,000 (5) Amount of new capital loan (NT$ thousand): 30,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 90,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Dong Lin Instruments Co., Ltd. (2) Relationship with the company providing capital loans: 100% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 60,000 (5) Amount of new capital loan (NT$ thousand): 30,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 90,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Hualin Co., Ltd. (2) Relationship with the company providing capital loans: 100% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 0 (5) Amount of new capital loan (NT$ thousand): 30,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 30,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: Fuh Kang Vitality Pharmaceutical Co., Ltd. (2) Relationship with the company providing capital loans: 50% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 200,000 (5) Amount of new capital loan (NT$ thousand): 50,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 250,000 (8) Reason for new capital loan: Operating funds required by the subsidiary

(1) Company name: SynerG Bio-Medical Long-Term Care Social Welfare Corporation (2) Relationship with the company providing capital loans: Over 50% owned subsidiary (3) Limit on capital loans (NT$ thousand): 762,952 (4) Original outstanding loan balance (NT$ thousand): 0 (5) Amount of new capital loan (NT$ thousand): 20,000 (6) Is the capital loan authorized by the board of directors for the chairperson to disburse in installments or for revolving use to the same borrowing entity: Yes (7) Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 20,000 (8) Reason for new capital loan: Operating funds required by the subsidiary 3. Collateral provided by the recipient of capital loans: (1) Content: None (2) Value (NT$ thousand): 0 4. Latest financial report of the recipient of capital loans: (1) Capital (NT$ thousand): 6,686,065 (2) Accumulated profit/loss (NT$ thousand): 113,103 5. Interest calculation method: Calculated from the borrowing date, interest rate 2%~3.5%. 6. Repayment: (1) Terms: Repaid within one year from the borrowing date, depending on financial situation. (2) Date: Repaid within one year from the borrowing date. 7. Outstanding capital loan balance as of the date of occurrence (NT$ thousand): 2,905,000 8. Ratio of outstanding capital loan balance to the net worth of the public company's latest financial report as of the date of occurrence: 38.00% 9. Source of company's funds lent to others: Parent company 10. Other matters that should be specified: None